- Home
- OKUR vs PRLD Comparison
OKUR vs PRLD Comparison
Compare OKUR & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- PRLD
- Stock Information
- Founded
- OKUR 2011
- PRLD 2016
- Country
- OKUR United States
- PRLD United States
- Employees
- OKUR N/A
- PRLD N/A
- Industry
- OKUR
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- OKUR
- PRLD Health Care
- Exchange
- OKUR NYSE
- PRLD Nasdaq
- Market Cap
- OKUR 76.6M
- PRLD 73.7M
- IPO Year
- OKUR N/A
- PRLD 2020
- Fundamental
- Price
- OKUR $2.89
- PRLD $0.81
- Analyst Decision
- OKUR Strong Buy
- PRLD Strong Buy
- Analyst Count
- OKUR 4
- PRLD 2
- Target Price
- OKUR $32.25
- PRLD $4.50
- AVG Volume (30 Days)
- OKUR 49.1K
- PRLD 279.1K
- Earning Date
- OKUR 05-14-2025
- PRLD 05-06-2025
- Dividend Yield
- OKUR N/A
- PRLD N/A
- EPS Growth
- OKUR N/A
- PRLD N/A
- EPS
- OKUR N/A
- PRLD N/A
- Revenue
- OKUR N/A
- PRLD $7,000,000.00
- Revenue This Year
- OKUR N/A
- PRLD N/A
- Revenue Next Year
- OKUR N/A
- PRLD N/A
- P/E Ratio
- OKUR N/A
- PRLD N/A
- Revenue Growth
- OKUR N/A
- PRLD N/A
- 52 Week Low
- OKUR $2.57
- PRLD $0.61
- 52 Week High
- OKUR $20.00
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- PRLD 57.52
- Support Level
- OKUR N/A
- PRLD $0.71
- Resistance Level
- OKUR N/A
- PRLD $0.72
- Average True Range (ATR)
- OKUR 0.00
- PRLD 0.08
- MACD
- OKUR 0.00
- PRLD 0.02
- Stochastic Oscillator
- OKUR 0.00
- PRLD 76.92
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.